ArticleGastro hep advances2025
The CancerenD24: A Novel Blood Test That Can Prevent Colorectal Cancer.
Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Colorectal cancer (CRC) typically develops over 10-15 years, providing a critical window for early detection and prevention. Precursor lesions, including neoplastic (adenomatous) and non-neoplastic (hyperplastic) polyps, can be detected via colonoscopy, which remains the only current modality capable of identifying precancerous lesions. However, colonoscopy is limited by its invasiveness, cost, and accessibility. This study evaluates CancerenD24, a simple blood-based assay measuring cluster of differentiation 24 (CD24) expression, for its ability to distinguish healthy individuals from those with adenomas or CRC. Methods: A total of 652 participants were enrolled at Tel Aviv Medical Center: 505 healthy controls, 22 with hyperplastic polyps, 25 with adenomatous polyps, and 100 with CRC. Healthy individuals underwent full screening, including colonoscopy, at the Integrated Cancer Prevention Center. Adenoma and CRC patients were recruited from gastroenterology, surgery, and oncology departments. CD24 expression was assessed by staining 10 Results: Mean CancerenD24 scores were significantly lower in healthy individuals (0.11 ± 0.01) compared to those with adenomas (0.26 ± 0.04) or CRC (0.45 ± 0.03), correlating with polyp size and histology. No gender-based differences were observed. Conclusion: CD24 levels increase early in CRC carcinogenesis, detectable already at the level of adenomas >5 mm. CancerenD24, as a noninvasive screening tool, shows promise as an aid to clinicians in identifying at-risk individuals and may reduce reliance on colonoscopy. Further validation is ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.